Loading…
Revelation Biosciences, Inc. is projected to rise to $1.28 by 2027, a +25% move from its current price of $1.02. REVB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.9879 | $1.02 | $1.05 | +0.09% |
| Aug 6 | $0.9754 | $1.02 | $1.07 | +0.17% |
| Aug 7 | $0.9662 | $1.02 | $1.08 | +0.26% |
| Aug 8 | $0.9585 | $1.02 | $1.09 | +0.34% |
| Aug 9 | $0.952 | $1.02 | $1.10 | +0.43% |
| Aug 10 | $0.9461 | $1.03 | $1.11 | +0.52% |
| Aug 11 | $0.9409 | $1.03 | $1.12 | +0.60% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.9409 | $1.03 | $1.12 | +0.60% |
| Week 2 | $0.9131 | $1.03 | $1.17 | +1.21% |
| Week 3 | $0.8936 | $1.04 | $1.21 | +1.82% |
| Week 4 | $0.8784 | $1.04 | $1.24 | +2.43% |
| Week 5 | $0.8657 | $1.05 | $1.28 | +3.05% |
| Week 6 | $0.855 | $1.06 | $1.31 | +3.67% |
| Week 7 | $0.8456 | $1.06 | $1.34 | +4.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. Its lead product candidate is Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response.
The company engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc.
in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Revelation Biosciences, Inc. trades under the symbol REVB. The current price is $0.9646 with a market cap of $3.77M and a market ranking of 5348.
The stock shows a defined 30-day technical picture and a forecast path that ranges from Neutral in 2026 to Bullish in many later years, with sizable upside potential indicated in the long-term forecasts. The forecast table provides year-by-year min/avg/max prices and ROI figures, culminating in a strong bullish outlook by 2050.
A major floor 21.9% below — a decisive break under it would weaken the trend.
The nearest floor, 6.9% below — buyers have tended to step in here.
The nearest ceiling, 15.7% above — a clean break opens room to run.
A major ceiling 23.5% above — clearing it would confirm fresh momentum.
Key REVB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of REVB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.00 | Buy | $0.9975 | Buy |
| MA 10 | $1.06 | Sell | $1.03 | Sell |
| MA 20 | $1.05 | Sell | $1.04 | Sell |
| MA 50 | $1.04 | Sell | $1.07 | Sell |
| MA 100 | $1.10 | Sell | $1.53 | Sell |
| MA 200 | $2.18 | Sell | $50.98 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.88 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -108.11 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -12.84 | Sell |
| Bollinger %B (20,2) | 0.15 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.12 | Buy |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 26.11 | Buy |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 0.95 | Buy |
| ADX (14) | 12.95 | Neutral |
| ATR (14) | 0.03 | Info |
Thirty-day snapshot shows a Bearish sentiment with RSI(14) at 40. The SMA50 is $1.05 and the SMA200 is $2.23, creating near-term resistance and support levels around the current price.
Key near-term support is at $0.96 and resistance at $1.18. The reported 30-day trading range spans from $0.7764 to $1.20, reflecting meaningful intra-month movement. Annualized volatility is 60, signaling notable variability around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.95 | $1.02 | $1.44 | 0% | Neutral | |
| $0.9999 | $1.28 | $1.73 | +25% | Bullish | |
| $0.9799 | $1.30 | $1.84 | +27% | Bullish | |
| $0.8837 | $1.20 | $1.77 | +18% | Neutral | |
| $0.8774 | $1.22 | $1.85 | +20% | Bullish | |
| $0.8604 | $1.23 | $1.90 | +21% | Bullish | |
| $0.7735 | $1.13 | $1.79 | +11% | Neutral | |
| $0.9312 | $1.39 | $2.24 | +36% | Bullish | |
| $1.06 | $1.61 | $2.66 | +58% | Bullish | |
| $1.04 | $1.61 | $2.69 | +58% | Bullish | |
| $1.05 | $1.78 | $3.19 | +75% | Bullish | |
| $1.76 | $3.45 | $6.85 | +238% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.95 | $1.02 | $1.21 | +0.00% |
| September 2026 | $0.8853 | $1.05 | $1.29 | +3.21% |
| October 2026 | $0.92 | $1.10 | $1.37 | +4.78% |
| November 2026 | $0.9138 | $1.10 | $1.38 | +0.01% |
| December 2026 | $0.9385 | $1.14 | $1.44 | +3.34% |
Click any year to see its month-by-month REVB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The REVB price prediction for 2026 points to an average of $1.02 (low $0.95, high $1.44) — a potential gain of 0% on today's $1.02. Price action looks broadly range-bound.
In 2027, REVB is projected to trade between $0.9999 and $1.73, averaging $1.28 — a potential gain of +25% from today's $1.02. That is up +25% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Revelation Biosciences, Inc.'s 2028 outlook centres on $1.30, within a $0.9799 to $1.84 range. That is up +1% on the projected 2027 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2029, REVB could reach as high as $1.77, with a base case around $1.20 and support toward $0.8837 — roughly +18% from $1.02. A consolidation phase looks the most probable path here.
Expect REVB to range from $0.8774 to $1.85 through 2030. The $1.22 average target implies a +20% move from current prices. That is up +2% on the projected 2029 average. Momentum favours further upside here.
The REVB price prediction for 2031 points to an average of $1.23 (low $0.8604, high $1.90) — a potential gain of +21% on today's $1.02. Buyers look set to stay in control over this stretch.
In 2032, REVB is projected to trade between $0.7735 and $1.79, averaging $1.13 — a potential gain of +11% from today's $1.02. That is -8% versus the projected 2031 average. Price action looks broadly range-bound.
Revelation Biosciences, Inc.'s 2033 outlook centres on $1.39, within a $0.9312 to $2.24 range. That is up +23% on the projected 2032 average. That marks a +36% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, REVB could reach as high as $2.66, with a base case around $1.61 and support toward $1.06 — roughly +58% from $1.02. Momentum favours further upside here.
Expect REVB to range from $1.04 to $2.69 through 2035. The $1.61 average target implies a +58% move from current prices. That is -1% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The REVB price prediction for 2040 points to an average of $1.78 (low $1.05, high $3.19) — a potential gain of +75% on today's $1.02. Momentum favours further upside here.
In 2050, REVB is projected to trade between $1.76 and $6.85, averaging $3.45 — a potential gain of +238% from today's $1.02. That is up +94% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in REVB today (≈ 980.392157 REVB) could be worth
$3,383.56
+$2,383.56 (+238%) by 2050 · US Dollar
Based on the average projected REVB price of $3.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in REVBwould be worth at today's price.
$1,000 invested in REVB on Jul 31, 2025 (≈ 100.401606 REVB) would be worth
$102.41
-$897.59 (-89.8%) today · 0.10× · US Dollar
Based on a REVB entry price of $9.96 vs. today's $1.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.06 | $962.26 | -3.8% |
| 1 month ago | $1.04 | $980.77 | -1.9% |
| 3 months ago | $1.12 | $910.71 | -8.9% |
| 6 months ago | $1.88 | $542.55 | -45.7% |
| 1 year ago | $9.96 | $102.41 | -89.8% |
| All time (5.0y) ago | $2,020,032 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our REVB forecast.
Our base-case forecast reaches $2.00 around 2050.
Implied market cap at $2.00: $7.82M
The multi-year forecast paints a mixed-to-bullish path after 2026. For 2026 the min/avg/max are $0.96 / $0.9646 / $1.38 with ROI 0 and Neutral sentiment.
From 2027 onward, the outlook shifts to Bullish in most years: 2027 min $0.946, avg $1.21, max $1.64, ROI 25.3; 2028 min $0.9189, avg $1.22, max $1.73, ROI 26.1; 2029 min $0.8422, avg $1.15, max $1.69, ROI 18.9; 2030 min $0.83, avg $1.16, max $1.75, ROI 20.2. The forecast remains broadly Neutral in 2031 and 2032 before reasserting Bullish momentum in 2033 and beyond.
Notable milestone years include 2033 with min $0.882, avg $1.32, max $2.13, ROI 36.5 and Bullish sentiment; 2034 with min $1.00, avg $1.53, max $2.52, ROI 58.4 and Bullish sentiment; 2035 with min $0.9848, avg $1.53, max $2.56, ROI 58.4 and Bullish sentiment. The long-range view extends to 2040 (min $0.9919, avg $1.68, max $3.02, ROI 73.9, Bullish) and 2050 (min $1.67, avg $3.30, max $6.56, ROI 241.9, Bullish).
Overall, the long-term outlook suggests meaningful upside with stronger average prices and higher max prices by 2040 and 2050, but several mid-cycle years show Neutral signals and modest ROI, underscoring the inherent uncertainty and risk in the forecast.
Tap a question to reveal the answer.
2030 forecast: min $0.83, avg $1.16, max $1.75 with ROI 20.2 and sentiment BULLISH.
Forecasts show an early Neutral in 2026 (avg $0.9646, min $0.96, max $1.38, ROI 0) and Bullish in 2027 (avg $1.21, ROI 25.3) through 2050 (avg $3.30, ROI 241.9). While this suggests upside potential, these are estimates and not guarantees, and risk remains given volatility and mixed mid-term signals.
Yes. The year-by-year max prices include 2033 $2.13, 2034 $2.52, 2035 $2.56, 2040 $3.02, and 2050 $6.56, indicating potential upside beyond $2 in several forecast years.
Current price is $0.9646 and market cap is $3.77M.
The 30-day range is $0.7764 to $1.20. Near-term support is at $0.96 and resistance at $1.18, with RSI(14) at 40, SMA50 at $1.05, SMA200 at $2.23, and annualized volatility 60.
Revelation Biosciences, Inc. Community Discussion
0Share your Revelation Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.